Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) Given Consensus Recommendation of "Buy" by Brokerages

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA - Get Free Report) has received a consensus rating of "Buy" from the nine brokerages that are presently covering the company, Marketbeat Ratings reports. Seven research analysts have rated the stock with a buy recommendation and two have assigned a strong buy recommendation to the company. The average 1 year price target among brokers that have updated their coverage on the stock in the last year is $24.13.

Several analysts have commented on TEVA shares. Truist Financial started coverage on shares of Teva Pharmaceutical Industries in a report on Wednesday, May 28th. They set a "buy" rating and a $25.00 target price on the stock. The Goldman Sachs Group started coverage on shares of Teva Pharmaceutical Industries in a report on Friday, June 6th. They set a "buy" rating and a $24.00 target price on the stock. JPMorgan Chase & Co. upgraded shares of Teva Pharmaceutical Industries from a "neutral" rating to an "overweight" rating and raised their target price for the stock from $21.00 to $23.00 in a report on Monday, May 12th. Bank of America lifted their price objective on shares of Teva Pharmaceutical Industries from $20.00 to $22.00 and gave the company a "buy" rating in a report on Thursday, May 8th. Finally, UBS Group lowered their price objective on shares of Teva Pharmaceutical Industries from $24.00 to $23.00 and set a "buy" rating on the stock in a report on Thursday, June 26th.

Insiders Place Their Bets

In related news, EVP Matthew Shields sold 6,206 shares of the business's stock in a transaction on Tuesday, June 3rd. The shares were sold at an average price of $17.02, for a total transaction of $105,626.12. Following the transaction, the executive vice president directly owned 9,989 shares in the company, valued at approximately $170,012.78. The trade was a 38.32% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 0.55% of the company's stock.

Hedge Funds Weigh In On Teva Pharmaceutical Industries

A number of institutional investors have recently added to or reduced their stakes in TEVA. Jones Financial Companies Lllp increased its holdings in Teva Pharmaceutical Industries by 145.4% during the fourth quarter. Jones Financial Companies Lllp now owns 8,592 shares of the company's stock worth $189,000 after buying an additional 5,091 shares during the last quarter. Charles Schwab Investment Management Inc. boosted its position in Teva Pharmaceutical Industries by 14.4% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 1,028,924 shares of the company's stock worth $22,677,000 after purchasing an additional 129,749 shares during the period. Assetmark Inc. boosted its position in Teva Pharmaceutical Industries by 1,370.3% during the fourth quarter. Assetmark Inc. now owns 5,205 shares of the company's stock worth $115,000 after purchasing an additional 4,851 shares during the period. Raymond James Financial Inc. bought a new position in Teva Pharmaceutical Industries during the fourth quarter worth $38,914,000. Finally, Callan Family Office LLC bought a new position in Teva Pharmaceutical Industries during the fourth quarter worth $207,000. 54.05% of the stock is currently owned by institutional investors and hedge funds.

Teva Pharmaceutical Industries Trading Down 1.0%

Teva Pharmaceutical Industries stock traded down $0.17 during midday trading on Monday, hitting $16.84. 9,689,108 shares of the stock were exchanged, compared to its average volume of 10,278,633. The company has a fifty day simple moving average of $17.03 and a two-hundred day simple moving average of $17.28. Teva Pharmaceutical Industries has a 52 week low of $12.47 and a 52 week high of $22.80. The stock has a market capitalization of $19.31 billion, a PE ratio of -14.64, a P/E/G ratio of 0.87 and a beta of 0.60. The company has a quick ratio of 0.74, a current ratio of 1.03 and a debt-to-equity ratio of 2.59.

Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last released its quarterly earnings data on Wednesday, May 7th. The company reported $0.52 earnings per share for the quarter, topping the consensus estimate of $0.47 by $0.05. The business had revenue of $3.89 billion for the quarter, compared to analyst estimates of $3.99 billion. Teva Pharmaceutical Industries had a negative net margin of 7.74% and a positive return on equity of 45.44%. Teva Pharmaceutical Industries's quarterly revenue was up 1.9% compared to the same quarter last year. During the same quarter last year, the firm earned $0.48 EPS. Equities research analysts anticipate that Teva Pharmaceutical Industries will post 2.5 EPS for the current fiscal year.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.